Investigating a new treatment for a severe lung disease after stem cell transplants
Bronchiolitis Obliterans: Discovery and Therapy
This study is looking at a lung condition called Bronchiolitis Obliterans Syndrome (BOS) that can happen after certain types of stem cell transplants, and it's testing a new drug, KD025, to see if it can help improve lung health for patients dealing with this tough issue.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10914143 on NIH RePORTER |
What this research studies
This research focuses on Bronchiolitis Obliterans Syndrome (BOS), a serious lung condition that can develop after allogeneic hematopoietic cell transplantation. The study aims to understand the disease's underlying mechanisms and test a new drug, KD025, which may help reverse the lung damage caused by BOS. By utilizing advanced lung organoid cultures and immunogenomics, researchers will identify the specific immune targets involved in BOS and evaluate the effectiveness of the treatment in a clinical trial. Patients participating in this research may contribute to significant advancements in the management of this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have developed Bronchiolitis Obliterans Syndrome following allogeneic hematopoietic cell transplantation.
Not a fit: Patients who have not undergone hematopoietic cell transplantation or those without a diagnosis of Bronchiolitis Obliterans Syndrome are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves lung function and survival rates for patients with BOS.
How similar studies have performed: Previous research has shown promise in treating related conditions with similar immunologic approaches, indicating potential for success in this novel treatment.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Cutler, Corey S — Dana-Farber Cancer Inst
- Study coordinator: Cutler, Corey S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.